Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-09
2011-08-09
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000
Reexamination Certificate
active
07994193
ABSTRACT:
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4353901 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4853394 (1989-08-01), King et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6479480 (2002-11-01), Moyes et al.
patent: 6486153 (2002-11-01), Castro Pineiro et al.
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 7253186 (2007-08-01), Andersson et al.
patent: 7601740 (2009-10-01), Weiner et al.
patent: 7659285 (2010-02-01), Weiner et al.
patent: 7732462 (2010-06-01), Weiner et al.
patent: 2002/0156068 (2002-10-01), Behan et al.
patent: 2002/0165225 (2002-11-01), Kankan et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0111399 (2006-05-01), Thvoesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thvoesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2006/0286610 (2006-12-01), Brann
patent: 2006/0292606 (2006-12-01), Brann
patent: 984843 (1976-03-01), None
patent: 0 005 318 (1979-11-01), None
patent: 0 061 333 (1982-09-01), None
patent: 0 379441 (1990-07-01), None
patent: 0 548 015 (1993-06-01), None
patent: 0 260 070 81 (1993-08-01), None
patent: 0 625 507 (1994-11-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: 51052176 (1976-05-01), None
patent: 5208517 (1977-07-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/17646 (1998-04-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 02/24649 (2002-03-01), None
patent: WO 02/076464 (2002-10-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
patent: WO 2006/104826 (2006-10-01), None
patent: WO 2004/039322 (2007-05-01), None
Borman et al., “5-HT2Breceptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro,”Br. J. Pharmacol., vol. 135, No. 5, pp. 1144-1151 (2002).
Adam, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers.Psychopharmacology, 99:219-221.
Adell, et al. 2005. Strategies for producing faster acting antidepressants.Drug Discovery Today, 10(8).578-585.
Akin, et al. 2004. Decreased serotonin 5-HT2Areceptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients.Neuropsychopharmacology, 29:2081-2087.
Alvisi, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria,Gazz. Chem. Ital. 22:158-168.
Antilla, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines.Organic Letters, 3(13):2077-2079.
Antilla, et al. 2002. The copper-catalyzed N-arylation of indoles.J. Am. Chem. Soc., 124:11684-11688.
Archibald, et al., 1974 “1,4-Bis-(2-indol-3-ylethyl)piperdines”J. Medicinal Chemistry, 17(7):745-747.
Archibald, et al., 1974 “Benzamidopiperdines. 2. Heterocyclic Compounds Related to Indoramin”J. Medicinal Chemistry, 17(7):736-739.
Archibald, et al., 1974 “Benzamidopiperdines. 3. Heterocyclic Compounds Related to Indoramin”J. Medicinal Chemistry, 17(7):739-744.
Artico, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase.Eur. J. Med. Chem., 27:219-228.
Bakshi, et al. 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.The Journal of Pharmacology and Experimental Therapeutics, 271 (2):787-794.
Barchas, J. 1973. Serotonin and Behavior. New York:Academic Press.
Barnes, et al. 1999. A review of central 5-HT receptors and their function.Neuropharmacology, 38:1083-1152.
Barr, et al. 1997. Agonist-independent activation of GZby the 5-hydroxytryptamine1Areceptor coexpressed inSpodoptera frugiperda cells. The Journal of Biological Chemistry, 272(52):32979-32987.
Bassus, et al. 1974. Psychotropes potentiels. X. Synthese de butyrophenones a cycle piperidine-spiro-tetrahydrooxazinone douees d'activite neuroleptique.Eur. J. Med. Chem.—Chimica Therapeutica, 9(4):416-423.
Bennett, et al. 1993. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.Neurology, 43:1551-1555.
Bhatia, et al. 1996. 5-Lipoxygenase inhibitors: Synthesis and structure-activity relationships of a series of 1-Aryl-2H,4H-tetrahydro-1 ,2,4-triazin-3-ones.J. Med. Chem., 39:3938-3950.
Biagi, et al. 1988. 1,2,3-Triazoles: Structural changes on two effective inhibitors of the prostaglandin synthesis in vitro.Farmaco Ed. Sci., 43:597-612.
Bibbiani, et al. 2001. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.Neurology, 57:1829-1834.
Birkmayer, et al. 1974. Nucleus ruber and L-Dopa psych
Andersson Carl-Magnus A.
Brann Mark R.
Davis Robert E.
Uldam Allan K.
Weiner David M.
ACADIA Pharmaceuticals Inc.
Jones Day
Kim Jennifer M
LandOfFree
Selective serotonin 2A/2C receptor inverse agonists as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective serotonin 2A/2C receptor inverse agonists as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective serotonin 2A/2C receptor inverse agonists as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726345